长期达巴万星治疗假体关节感染后葡萄球菌耐药性的出现
本研究探讨长期达巴万星治疗假体关节感染或骨科植入物感染后,体内是否出现达巴万星耐药葡萄球菌。对19例接受≥12周达巴万星治疗的患者和25例对照患者采样,结果显示4例治疗患者携带达巴万星耐药表皮葡萄球菌,对照组无耐药菌(P=0.029)。
要点
- 长期达巴万星治疗可诱导体内出现达巴万星耐药表皮葡萄球菌。
- 耐药菌MIC值范围为0.38-0.75 mg/L,高于EUCAST耐药折点0.25 mg/L。
- 治疗患者耐药菌检出率与对照组差异有统计学意义(P=0.029)。
核心结论
- 长期达巴万星治疗假体关节感染或骨科植入物感染后,患者体内可出现达巴万星耐药葡萄球菌。
研究设计与样本
- 研究纳入19例接受长期达巴万星治疗(≥12周)的假体关节感染或骨科植入物感染患者,以及25例择期假体关节手术对照患者。
- 从鼻孔和会阴采样,在含达巴万星浓度0.0、0.125、0.5和2.0 mg/L的Mueller-Hinton II琼脂平板上传代培养。
- 用MALDI-TOF分析葡萄球菌菌落生长,并用梯度试验法测定达巴万星MIC值。
主要发现
- 19例达巴万星治疗患者中,4例检出达巴万星耐药葡萄球菌(MIC>0.25 mg/L,依据EUCAST折点表)。
- 4株耐药菌均为表皮葡萄球菌,3株来自鼻孔,1株来自会阴,MIC值分别为0.38、0.38、0.5和0.75 mg/L。
- 对照组25例样本中未检出耐药葡萄球菌(P=0.029,Fisher精确检验)。
关键数值与推荐
- 达巴万星耐药判定依据EUCAST折点表,MIC>0.25 mg/L为耐药。
- 耐药菌MIC值范围为0.38-0.75 mg/L。
临床怎么用
- 对接受长期达巴万星治疗的患者,应关注达巴万星耐药葡萄球菌的出现,尤其表皮葡萄球菌。
- 治疗期间或复发时,可考虑进行达巴万星药敏试验以指导治疗决策。
局限性
- 样本量较小(治疗组19例,对照组25例)。
- 仅从鼻孔和会阴采样,未覆盖其他部位。
- 未报告耐药菌出现的具体时间点和临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Dalbavancin, a lipoglycopeptide with a half-life of 150-200 h, is a promising treatment option for prosthetic joint infections (PJIs) and other orthopaedic implant-associated infections (IAIs) caused by multidrug-resistant staphylococci. However, in vitro studies have shown that when exposed to low concentrations of dalbavancin, staphylococcal strains resistant to dalbavancin can emerge, potentially affecting its effectiveness in cases of recurrent infection. To investigate whether dalbavancin-resistant staphylococci emerge in vivo following long-term dalbavancin treatment for PJIs or orthopaedic IAIs. PATIENTS AND METHODS: Nineteen patients who had received long-term dalbavancin treatment (≥12 weeks) following PJI or orthopaedic IAI and 25 control patients scheduled for elective prosthetic joint surgery were sampled from the nares and perineum. Each sample was subcultured on Mueller-Hinton II agar plates containing various concentrations of dalbavancin (0.0, 0.125, 0.5, and 2.0 mg/L). The growth of staphylococcal colonies was analysed using MALDI-TOF, and the MIC values of dalbavancin were determined using the gradient test method. RESULTS: Among dalbavancin-treated patients, 4 out of 19 displayed staphylococcal species resistant to dalbavancin (MIC value >0.25 mg/L according to EUCAST breakpoint tables). These four were all Staphylococcus epidermidis isolates, three from the nares and one from the perineum, and displayed MIC values of 0.38, 0.38, 0.5, and 0.75 mg/L. No resistant staphylococci were detected in the samples from the control group (P = 0.029, Fisher's exact test). CONCLUSIONS: The present study demonstrated the emergence of dalbavancin-resistant staphylococci following long-term treatment.
引用
- Hugg R, Stegger M, Söderquist B, et al. Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections. J Antimicrob Chemother. 2026. PMID: 42372046. doi:10.1093/jac/dkag218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。